154 related articles for article (PubMed ID: 24637708)
1. Immunogenicity of Escherichia coli expressed envelope 2 protein of Chikungunya virus.
Tripathi NK; Priya R; Shrivastava A
Bioengineered; 2014; 5(3):198-203. PubMed ID: 24637708
[TBL] [Abstract][Full Text] [Related]
2. Development of a pilot-scale production process and characterization of a recombinant Japanese encephalitis virus envelope domain III protein expressed in Escherichia coli.
Tripathi NK; Shrivastava A; Biswal KC; Rao PV
Appl Microbiol Biotechnol; 2012 Sep; 95(5):1179-89. PubMed ID: 22562165
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Ramsauer K; Schwameis M; Firbas C; Müllner M; Putnak RJ; Thomas SJ; Desprès P; Tauber E; Jilma B; Tangy F
Lancet Infect Dis; 2015 May; 15(5):519-27. PubMed ID: 25739878
[TBL] [Abstract][Full Text] [Related]
4. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
Weber C; Büchner SM; Schnierle BS
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
[TBL] [Abstract][Full Text] [Related]
5. Production of recombinant Chikungunya virus envelope 2 protein in Escherichia coli.
Tripathi NK; Priya R; Shrivastava A
Appl Microbiol Biotechnol; 2014 Mar; 98(6):2461-71. PubMed ID: 24337252
[TBL] [Abstract][Full Text] [Related]
6. Expression, purification and evaluation of diagnostic potential and immunogenicity of dengue virus type 3 domain III protein.
Reddy PB; Pattnaik P; Tripathi NK; Srivastava A; Rao PV
Protein Pept Lett; 2012 May; 19(5):509-19. PubMed ID: 22486646
[TBL] [Abstract][Full Text] [Related]
7. Chikungunya E2 Protein Produced in
Bagno FF; Godói LC; Figueiredo MM; Sérgio SAR; Moraes TFS; Salazar NC; Kim YC; Reyes-Sandoval A; da Fonseca FG
Viruses; 2020 Aug; 12(9):. PubMed ID: 32858804
[TBL] [Abstract][Full Text] [Related]
8. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
[TBL] [Abstract][Full Text] [Related]
9. High yield expression and purification of Chikungunya virus E2 recombinant protein and its evaluation for serodiagnosis.
Verma A; Chandele A; Nayak K; Kaja MK; Arulandu A; Lodha R; Ray P
J Virol Methods; 2016 Sep; 235():73-79. PubMed ID: 27180040
[TBL] [Abstract][Full Text] [Related]
10. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.
Chua CL; Sam IC; Merits A; Chan YF
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004960. PubMed ID: 27571254
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice.
Babu JP; Pattnaik P; Gupta N; Shrivastava A; Khan M; Rao PV
Vaccine; 2008 Aug; 26(36):4655-63. PubMed ID: 18640168
[TBL] [Abstract][Full Text] [Related]
12. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice.
Khan M; Dhanwani R; Rao PV; Parida M
Virus Res; 2012 Aug; 167(2):236-46. PubMed ID: 22610133
[TBL] [Abstract][Full Text] [Related]
13. An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.
Ge N; Sun J; Liu Z; Shu J; Yan H; Kou Z; Wei Y; Jin X
Virol Sin; 2022 Apr; 37(2):266-276. PubMed ID: 35527225
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of neutralizing antibodies produced by papaya mosaic virus nanoparticles fused to the E2EP3 peptide epitope of Chikungunya envelope.
Nor Rashid N; Teoh TC; Al-Harbi SJ; Yusof R; Rothan HA
Trop Biomed; 2021 Mar; 38(1):36-41. PubMed ID: 33797522
[TBL] [Abstract][Full Text] [Related]
16. An in vitro refolding method to produce oligomers of anti-CHIKV, E2-IgM Fc fusion subunit vaccine candidates expressed in E. coli.
Kumar S; Singh VK; Vasam M; Patil PS; Dhaked RK; Ansari AS; Lohiya NK; Parashar D; Tapryal S
J Immunol Methods; 2020 Dec; 487():112869. PubMed ID: 32971119
[TBL] [Abstract][Full Text] [Related]
17. Enzyme-linked immunosorbent assay using recombinant envelope protein 2 antigen for diagnosis of Chikungunya virus.
Fumagalli MJ; de Souza WM; Espósito DLA; Silva A; Romeiro MF; Martinez EZ; da Fonseca BAL; Figueiredo LTM
Virol J; 2018 Jul; 15(1):112. PubMed ID: 30041676
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of baculovirus-expressed Chikungunya virus E1 envelope proteins for serodiagnosis of Chikungunya infection.
Kumar P; Pok KY; Tan LK; Angela C; Leo YS; Ng LC
J Virol Methods; 2014 Sep; 206():67-75. PubMed ID: 24880071
[TBL] [Abstract][Full Text] [Related]
19. Producing physicochemical property consensus alphavirus protein antigens for broad spectrum vaccine design.
Baker WS; Negi S; Braun W; Schein CH
Antiviral Res; 2020 Oct; 182():104905. PubMed ID: 32800880
[TBL] [Abstract][Full Text] [Related]
20. Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine.
Bao H; Ramanathan AA; Kawalakar O; Sundaram SG; Tingey C; Bian CB; Muruganandam N; Vijayachari P; Sardesai NY; Weiner DB; Ugen KE; Muthumani K
Viral Immunol; 2013 Feb; 26(1):75-83. PubMed ID: 23409931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
